Their clinical and multi-omics data analysis revealed that in comparison with HR-/HER2+ breast cancer, patients with triple-positive breast cancer generally have smaller tumor diameters, relatively lower lymph node metastasis rates, and better prognoses. This evidence concerns the gene ERBB2 and breast cancer.